Ismidenon is under clinical development by AmyriAD Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ismidenon’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ismidenon overview

Ismidenon (AD-101) is under development for the treatment of cognition and global function of Alzheimer's disease. It is administered through oral route in the form of tablet. The drug candidate acts by targeting CaV3.1 and CaV3.3 voltage-gated calcium channels.

It was under development for the treatment of essential tremor.

AmyriAD Therapeutics overview

AmyriAD Therapeutics (AmyriAD) is developing drug treatments in conjunction with diagnostics, digital staging assessments, and disease mitigation strategies. AmyriAD is headquartered in Los Angeles, California, the US.

For a complete picture of Ismidenon’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.